Nanatinostat (CHR-3996; Tractinostat; VRx-3996) is a novel, oral, and hydroxamic acid-based HDAC inhibitor (IC50 of 8 nM) with potential anticancer activity. By inhibiting HDAC, Nanatinostat causes an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes, ultimately leading to the inhibition of tumor cell division and the induction of tumor cell apoptosis.

纯度：≥98%

CAS：1256448-47-1